Sorrento Therapeutics Inc.

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for pain management, cancer, inflammation and autoimmune diseases. Sorrento's lead product candidates include late-stage pain drugs, therapeutic antibodies for cancer, inflammation and autoimmune diseases, as well as clinical stage immune-cellular therapies targeting solid tumors.

Expert Comments:

"We, as a firm, have been watching Sorrento since its inception because we've been looking at the monoclonal antibody field for a long time. . .the company had full pipeline of oncology candidates. It was really impressive to me. And it had achieved that with a mere 18 employees. . .this is what pharma 2.0 needs to look like—guys that are churning out phenomenal pipelines of new, innovative products with relatively small human capital but genuine innovation, genuine creativity. . .[In Sorrento's CEO] you have both scientific brilliance and commercial acumen. He's really built a company that I think investors should watch more than any other in the space right now. . .frankly, if everything plays out through the clinical trials process, that will position the company as one of the greatest biotechs in history." read more >

"A promising aspect of the immunotherapy proposition, as it pertains to Sorrento Therapeutics Inc. particularly, is potentially quicker access to the market, according to Chen Lin. 'For a therapy from Sorrento, I would look for a 505(b)(2) pathway,' he said." read more >

"Sorrento Therapeutics Inc.'s management has been very clear it views the company as an idea generator, as a relentless innovator. . .the company is emblematic of [other companies in the sector] in that they are going to wind up seeking and potentially establishing significant strategic partnerships geared toward the commercialization of their individual specific therapeutic entities; this is something that investors should watch for very closely. . .in the case of Sorrento and LA Cell, this is very early-stage work. Nothing has been progressed into the clinic. I would anticipate that we should see the first investigational new drug (IND) application filed [in 2016], and potentially the first clinical development milestones reached a year after that. . .there is enough evidence for investors to at least be intrigued." read more >

Experts Following This Company

Michael G. King, Jr., Managing Director and Senior Biotechnology Analyst – JMP Securities
Jason Kolbert, Senior Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters, the company and other contributors.

Sorrento Therapeutics Inc. is a former billboard advertiser of Streetwise Reports. The company's advertising fees paid for Streetwise Reports to create this "Investor Summary Page," to which links were placed on Streetwise Reports' websites and newsletters. Streetwise Reports did not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.